Lupin receives USFDA approval to launch Calcium Acetate Capsules

26 Oct 2015 Evaluate

Lupin’s US subsidiary - Lupin Pharmaceuticals Inc., has launched its Calcium Acetate Capsules, 667 mg (169 mg Calcium) having received final approval from the United States Food and Drug Administration (USFDA).

Lupin’s Calcium Acetate Capsules, 667 mg (169 mg Calcium) are the AB rated generic equivalent of Fresenius Medical Care North America’s (Fresenius) PhosLo Gelcaps 667 mg (169 mg Calcium) and are indicated for the control of hyperphosphatemia in end stage renal failure. PhosLo Gelcaps had annual US sales of $54.5 million, as per IMS MAT March, 2015.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.


Lupin Share Price

1601.00 -4.35 (-0.27%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.